Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-01

Clinical Trial Update: Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs [Phase 3]

View source ↗

Summary

Phase 3 study in Chinese participants with gastroenteropancreatic neuroendocrine tumors has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lanreotide Autogel (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Status: COMPLETED | Results posted: 2024-10-01